Cargando…
Integrative Hematology: State of the Art
Blood cancers are a group of diseases with thus far frequently poor prognosis. Although many new drugs, including target therapies, have been developed in recent years, there is still a need to expand our therapeutic armamentarium to better deal with these diseases. Integrative hematology was concei...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864076/ https://www.ncbi.nlm.nih.gov/pubmed/36675247 http://dx.doi.org/10.3390/ijms24021732 |
_version_ | 1784875493485445120 |
---|---|
author | Andreazzoli, Francesca Bonucci, Massimo |
author_facet | Andreazzoli, Francesca Bonucci, Massimo |
author_sort | Andreazzoli, Francesca |
collection | PubMed |
description | Blood cancers are a group of diseases with thus far frequently poor prognosis. Although many new drugs, including target therapies, have been developed in recent years, there is still a need to expand our therapeutic armamentarium to better deal with these diseases. Integrative hematology was conceived as a discipline that enriches the patient’s therapeutic possibilities with the use of supplements, vitamins and a nutritional approach aiming at improving the response to therapies and the clinical outcome. We will analyze the substances that have proved most useful in preclinical and clinical studies in some of the most frequent blood diseases or in those where these studies are more numerous; the importance of the nutritional approach and the role of the intestinal microbiota will also be emphasized. |
format | Online Article Text |
id | pubmed-9864076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98640762023-01-22 Integrative Hematology: State of the Art Andreazzoli, Francesca Bonucci, Massimo Int J Mol Sci Review Blood cancers are a group of diseases with thus far frequently poor prognosis. Although many new drugs, including target therapies, have been developed in recent years, there is still a need to expand our therapeutic armamentarium to better deal with these diseases. Integrative hematology was conceived as a discipline that enriches the patient’s therapeutic possibilities with the use of supplements, vitamins and a nutritional approach aiming at improving the response to therapies and the clinical outcome. We will analyze the substances that have proved most useful in preclinical and clinical studies in some of the most frequent blood diseases or in those where these studies are more numerous; the importance of the nutritional approach and the role of the intestinal microbiota will also be emphasized. MDPI 2023-01-15 /pmc/articles/PMC9864076/ /pubmed/36675247 http://dx.doi.org/10.3390/ijms24021732 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Andreazzoli, Francesca Bonucci, Massimo Integrative Hematology: State of the Art |
title | Integrative Hematology: State of the Art |
title_full | Integrative Hematology: State of the Art |
title_fullStr | Integrative Hematology: State of the Art |
title_full_unstemmed | Integrative Hematology: State of the Art |
title_short | Integrative Hematology: State of the Art |
title_sort | integrative hematology: state of the art |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864076/ https://www.ncbi.nlm.nih.gov/pubmed/36675247 http://dx.doi.org/10.3390/ijms24021732 |
work_keys_str_mv | AT andreazzolifrancesca integrativehematologystateoftheart AT bonuccimassimo integrativehematologystateoftheart |